Buzzing :

Greece in crisisTravel & Budget & EuropeSaaS $ Email MarketingHarnautBlacklisting Policy 2Question Paper Leak 2A big moment for small armsAI in Financial Markets: How Technology is Changing Investing'India's size and diversity make it a powerful innovation engine'Datanomics: Housing, gold loans drive household debt to a decade highSamrat ChoudharyEl Nino
Home / Company / Quarterly Results / Gland Pharma Ltd Quarterly Results

Gland Pharma Ltd Quarterly Results

Q4 FY25-26 Results Summary

Revenue

The revenue stands at ₹1,742.79 crore, reflecting a quarter-on-quarter *(QoQ) increase of 2.80 per cent from ₹1,695.36 crore. This corresponds to a year-on-year *(YoY) growth of 22.31 per cent.

Operating Profit

Operating Profit stands at ₹121.50 crore, reflecting a quarter-on-quarter *(QoQ) increase of 81.07 per cent from ₹67.10 crore. This corresponds to a year-on-year *(YoY) growth of 136.01 per cent.

PBDT

PBDT stands at ₹247.78 crore, reflecting a quarter-on-quarter *(QoQ) increase of 18.95 per cent from ₹208.30 crore. This corresponds to a year-on-year *(YoY) growth of 25.43 per cent.

Profit Before Tax

Profit Before Tax stands at ₹505.80 crore, reflecting a quarter-on-quarter *(QoQ) increase of 39.67 per cent from ₹362.13 crore. This corresponds to a year-on-year *(YoY) growth of 75.42 per cent.

Net Profit

Net Profit stands at ₹366.68 crore, reflecting a quarter-on-quarter *(QoQ) increase of 28.29 per cent from ₹285.83 crore. This represents a 96.57 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Gland Pharma Ltd News

premium

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

2 min read
premium

Gland Pharma stock seen underperforming after acquiring France's Cenexi

3 min read
premium

Gland Pharma enters into agreement to acquire Cenexi; stock slips 5%

3 min read
premium

Gland Pharma plunges 13%, hits 52-week low on disappointing Q2 results

3 min read

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%

2 min read
premium

Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil

1 min read
More

Gland Pharma Ltd Earnings

CategoryQ4 FY25-26Q4 FY24-25Change %FY24-25FY23-24Change %
Total Revenue1,742.791,424.9122.315,664.723,624.6056.29
Expenses1,229.771,077.3914.144,331.652,656.3063.07
Other Income111.4744.03153.17170.24240.46-29.20
Operating Profit121.5051.48136.011,503.311,208.7724.37
Depreciation108.6695.7613.47344.57146.74134.82
Interest10.037.4534.6326.207.45251.68
Profit Before Tax505.80288.3375.421,132.541,054.587.39
Tax139.12101.7936.67345.75276.3425.12
Net Profit366.68186.5496.57772.46781.04-1.10
CategoryQ4 FY25-26Q3 FY25-26Change %
Total Revenue1,742.791,695.362.80
Expenses1,229.771,284.83-4.29
Other Income111.4763.1776.46
Operating Profit624.49473.7031.83
Depreciation108.66107.650.94
Interest10.033.93155.22
Profit Before Tax505.80362.1339.67
Tax143.97109.0532.02
Net Profit366.68261.4840.23

Gland Pharma Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Buy 1,841Elara Capital04-Feb-2025
Buy 1,970Motilal Oswal06-Nov-2024

Gland Pharma Ltd Financial Reports

Data not available.

Gland Pharma Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Gland Pharma61.00%-13.82%5.42%7.46%39.06%29.07%
Glaxosmi. Pharma4.96%-1.83%6.26%15.23%0.49%-5.32%
Ipca Labs.28.97%-7.51%-1.64%10.73%17.95%24.44%
Ajanta Pharma42.06%-6.62%0.77%12.50%16.44%32.32%
J B Chemicals &51.06%--8.35%17.83%37.99%
Emcure Pharma104.80%4.33%4.92%12.62%36.38%31.09%
Wockhardt62.10%3.01%5.51%19.01%43.00%34.71%

Gland Pharma Ltd Corporate Information

Chairman / Executive Director / MD / CEO: SRINIVAS SADU
Independent Non Exe. Director: UDO JAHANNES VETTER
Independent Non Exe. Director: ESSAJI GOOLAM VAHANVATI
Non-Exec & Non-Independent Dir: Jia Ai (Allen) Zhang
Independent Non Exe. Director: Naina Lal Kidwai
Non-Exec & Non-Independent Dir: Wenjie Zhang
Non-Exec & Non-Independent Dir: Wei Huang
CS / Compliance Officer / Vice President: SAMPATH KUMAR PALLERLAMUDI
Additional Director: William Robert Keller

Gland Pharma Ltd News

No More Data

More